Nephrotic syndrome.
Publication/Presentation Date
3-1-2015
Abstract
On the basis of observational studies, the most common cause of nephrotic syndrome in school-aged children is minimal change disease. On the basis of research evidence and consensus, corticosteroids are considered first-line therapy for treatment of nephrotic syndrome. On the basis of consensus, prednisone therapy should be initiated at doses of 60 mg/m2 per day (2 mg/kg per day) administered for 4 to 6 weeks, followed by 40 mg/m2 per dose (1.5 mg/kg) every other day for at least 6 to 8 weeks. On the basis of consensus and expert opinion, it is important to recognize and manage the complications that can arise in patients with nephrotic syndrome, such as dyslipidemia, infection, and thrombosis. On the basis of research evidence, consensus, and expert opinion, several alternative therapies have been observed to have variable efficacy in children with both corticosteroid-dependent and corticosteroid-resistant nephrotic syndrome, although caution must be exercised in the administration of these corticosteroid-sparing medications secondary to toxic adverse effects. On the basis of observational studies, the course of nephrotic syndrome in most patients is that of relapse and remission.
Volume
36
Issue
3
First Page
117
Last Page
125
ISSN
1526-3347
Published In/Presented At
Andolino, T. P., & Reid-Adam, J. (2015). Nephrotic syndrome. Pediatrics in review, 36(3), 117–129. https://doi.org/10.1542/pir.36-3-117
Disciplines
Medicine and Health Sciences | Pediatrics
PubMedID
25733763
Department(s)
Department of Pediatrics
Document Type
Article